Role of metronomics in cancer clinical trials and practice in developing countries
Role of metronomics in cancer clinical trials and practice in developing countries
Latest on the WINTHER trial
Developments with PD1 and immunotherapy in melanoma
Challenges and opportunities for implementing personalized medicine in Brazil
Demonstrating the value of genomic cancer medicine
Strategies to address inter- and intra- patient tumour heterogeneity: PANGEA
Battling therapeutic resistance
Improving predictability of clinical trial outcomes
2013 WIN Symposium: 'Innovation to implementation'
Delivering stratified medicine using next generation sequencing
Development of information systems that identify genomic biomarkers
Establishing immunotherapy as a standard in cancer treatment
Molecular stratification identifies exceptional responders to therapy for pancreatic cancer
Development of clinical decision support tools for physicians and patients
Identifying and applying molecular subgrouping in colorectal cancer
Involvement in the WIN Consortium
Implementation of individualised treatment and the WINTHER trial
The 2013 WIN Symposium
Importance of personalised medicine and the WIN Consortium
The role of physicians and researchers in the medical community
Achievements of the WIN Consortium
Goal of the 2013 WIN Symposium